ASCO24 . LURBINECTEDIN Versus PLATINUM Rechallenge in RELAPSED EXTENSIVE STAGE SMALL CELL LUNG CÁNCER ( SEGUNDA LÍNEA ) : A Retrospective Cohort Study . PFS PLATINO : 4,37 MESES . PFS LURBINECTEDIN : 2,63 MESES . OS PLATINO : 8,61 MESES . OS LURBINECTEDIN : 4,7 MESES .

Median PFS Was 4.37 (1.53, 5.94) Vs. 2.63 Months (1.68, 4.40) ( P = 0.030) And Median OS Was 8.61 (4.91, 14.26) Vs. 4.70 Months (2.63, 6.73) ( P = 0.001) For Platinum Rechallenge And LURBINECTEDIN, Respectively .